Cart
sales@molnova.com
Otilimab
CAS No. 1638332-55-4
Otilimab( —— )
Catalog No. M36826 CAS No. 1638332-55-4
Otilimab (GSK 3196165) is a humanized monoclonal antibody against granulocyt-macrophage colony-stimulating factor (GM-CSF).
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 306 | In Stock |
|
| 10MG | 522 | In Stock |
|
| 25MG | 829 | In Stock |
|
| 50MG | 1088 | In Stock |
|
| 100MG | 1469 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameOtilimab
-
NoteResearch use only, not for human use.
-
Brief DescriptionOtilimab (GSK 3196165) is a humanized monoclonal antibody against granulocyt-macrophage colony-stimulating factor (GM-CSF).
-
DescriptionOtilimab (GSK 3196165) is an anti-granulocyte-macrophage colony-stimulating factor (GM-CSF) humanized monoclonal antibody. Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayTyrosine Kinase
-
TargetCSF1R
-
RecptorCSF-1R
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1638332-55-4
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Senolt L. Emerging therapies in rheumatoid arthritis: focus on monoclonal antibodies. F1000Res. 2019 Aug 30;8:F1000 Faculty Rev-1549.?
molnova catalog
related products
-
Pexidartinib
An oral-active, BBB-penatrant, potent mutil-targeted RTK inhibitor of CSF-1R, Kit, and Flt3 with IC50 of 20 nM, 10 nM and 160 nM, respectively.
-
BLZ945
BLZ945 (BLZ-945) is a potent, selective, brain-penetrant CSF-1R inhibitor with biochemical IC50 of 1 nM.
-
Plonmarlimab
Plonmarlimab (TJ003234) is an anti-macrophage colony-stimulating factor (GM-CSF) monoclonal antibody with potential antiviral activity for the study of immune diseases and novel coronavirus infections.
